



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application

Inventor(s): G. Ganga Raju

Appln. No.: 09/463,024

Confirm. No.: 5778

Filed: February 15, 2002

Title: HYDROXYCITRIC ACID COMPOSITIONS,
PHARMACEUTICAL AND DIETARY
SUPPLEMENTS AND FOOD PRODUCTS
MADE THEREFROM, AND METHODS FOR
THEIR USE IN REDUCING BODY WEIGHT

PATENT APPLICATION

Art Unit: 1615

Examiner: Vanik, David L.

Atty. Docket No.: IHEAL-01063US1

Customer No. 23910

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

05/30/2006 AKELECH1 00000028 09463024
01 FC:1806

180.00 00

Sir:

It is requested that the information identified in this statement be considered by the Examiner and made of record in the above-identified application. This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56. If this is a continuation, divisional or continuation-in-part application, it is understood that the Examiner will consider all information which was considered by the Office in a parent application. MPEP §609. Such information therefore is not listed herein unless it is desired that the information be printed on a patent issuing from the subject application.

Enclosed with this statement are the following:

- X Form PTO-1449. The Examiner is requested to initial the form and return it to the undersigned in accordance with M.P.E.P. §609.
- X Copies of cited U.S. patents and publications are not enclosed. However, copies of cited foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98(a)(2), as required, except for those items designated by an asterisk (*), which were previously submitted by the applicant in a parent application, from which benefit under 35 U.S.C. §120 is claimed, with an *Information Disclosure Statement* submitted in the parent application which complies with the September 8, 2000 or subsequent revision of 37 C.F.R. §1.98(a-c), as allowed under 37 C.F.R. §1.98(d)(1).
- X If any of the cited/submitted documents is in a foreign language, a concise explanation of relevance is provided pursuant to 37 C.F.R. §1.98(a)(3)(i). For foreign language documents cited in a search report by a foreign patent office, the requirement for a concise explanation of relevance is satisfied by the submission herewith of an English language version of the search report. MPEP §609A(3). If a written English-language translation of a non-English language document, or portion thereof, is within the possession, custody or control of, or is readily available to any individual designated in §1.56(c), a copy of the translation accompanies this statement, 37 C.F.R. §1.98(a)(3)(ii), and satisfies the requirement for a concise explanation of relevance, MPEP §609A(3).

— **PTA Statement under 37 C.F.R. §1.704(d).** Each item of information contained in the *Information Disclosure Statement* was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the *Information Disclosure Statement*.

This statement should be considered because:

 X **37 C.F.R. §1.97(c).** Although it may not qualify under subsection (b), this statement qualifies under 37 C.F.R. §1.97, subsection (c) because:

- (1) It is being filed before the mailing date of a FINAL Office Action, a Notice of Allowance, or an action that otherwise closes prosecution in the subject application, whichever occurs first.

-- AND (check at least one of the following) --

- (1) It is accompanied by a STATEMENT as set forth in 37 C.F.R. §1.97(e).

-- OR --


- X (2) It is accompanied by the \$180 fee set forth in 37 C.F.R. §1.17(p).

 X ***Fee Authorization.*** The Commissioner is hereby authorized to charge any deficiencies or credit any overpayment to Deposit Account No. 06-1325. ***A duplicate copy of this authorization is enclosed.***

Respectfully submitted,

FLIESLER MEYER LLP

Date: 5/20/06

By: 
Sheldon R. Meyer
Reg. No. 27,660

FLIESLER MEYER LLP
Four Embarcadero Center, Fourth Floor
San Francisco, California 94111-4156
Telephone: (415) 362-3800
Facsimile: (415) 362-2928
Customer No. 23910



Form PTO-1449 (Substitute) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE <i>Information Disclosure Statement BY APPLICANT (Use several sheets if necessary)</i>	Attorney Docket Number IHEAL-01063US1	Serial/Patent Number 09/463,024
	Applicant/Patent Owner G. Ganga Raju	
	Filing/Issue Date Feb. 15, 2002	Group Art Unit 5778

U.S. PATENTS

Examiner Initial		Patent Number	Issue Date	First Named Inventor	Class	Subclass	Filing Date
		5,911,992	June 15, 1999	Braswell et al.			
		5,981,510	Nov. 9, 1999	Fujiwara et al.			
		6,034,125	Mar 7, 2000	Malcolm N. McLeod			
		6,048,846	Nov. 9, 1999	Cochran			
		6,100,251	Aug. 8, 2000	De la Harpe et al.			
		6,203,819	Mar. 20, 2001	Fine			
		6,258,848	Jul 10, 2001	I. George Fantus			
		6,291,533	Sep. 18, 2001	Fleishner			
		6,352,713	Mar. 5, 2002	Kirschner et al.			
		6,541,026	Apr. 1, 2003	Siskind			
		6,589,566	Jul. 8, 2003	Ueda et al.			
		6,809,115	Oct. 26, 2004	Katz et al.			
		6,967,030	Nov. 22, 2005	Wright et al.			


U.S. PATENT PUBLICATIONS

Examiner Initial		Patent Application Publication Number	Publication Date	Applicant
		2001/0031744	Oct. 18, 2001	Kosbab
		2003/0220329	Nov. 27, 2003	Surwit et al.

PENDING U.S. PATENT APPLICATIONS

Examiner Initial		Application Number	Filing Date	First Named Inventor	Petition to Expunge? Yes No
		09/463,024	Feb 15, 2002	G. Ganga Raju	

FOREIGN PATENT DOCUMENTS

Form PTO-1449 (Substitute) 	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Information Disclosure Statement BY APPLICANT (Use several sheets if necessary)		Attorney Docket Number IHEAL-01063US1	Serial/Patent Number 09/463,024
	Applicant/Patent Owner G. Ganga Raju			
	Filing/Issue Date Feb. 15, 2002	Group Art Unit 5778		

Examiner Initial	Document Number	Publication Date	Country	Class	Subclass	Trans- lation Yes No	
	WO 89/10357	2 Nov 1989	PCT				
	EP 0 714 663	5 Jun 1996	EPO				

OTHER DOCUMENTS (Include author (if any), title, publisher and place of publication, date and pertinent pages)

	Chen S., et al., "More direct evidence for a malonyl-CoA-carnitine palmitoyltransferase I interaction as a key event in pancreatic beta-cell signaling," <i>Diabetes</i> , Vol. 43(7), pp. 878-883 (1994).
	Cloutre, Dallas, et al., "The Diet and health benefits of HCA – How this all-natural diet aid promotes weight loss and inhibits fat production," <i>A Keats Good Health Guide</i> (1994).
	Fried, Susan K. et al., "Role of fatty acid synthesis in the control of insulin-stimulated glucose utilization by rat adipocytes," <i>Journal of Lipid Research</i> , Vol. 22, pp. 753-762 (1981).
	Halford, Jason et al., "Separate systems for serotonin and leptin in appetite control," <i>The Finnish Medical Society Duodecim, Ann Med</i> 2000; 32: 222-232.
	Murray, Michael T., "Encyclopedia of Nutritional Supplements, The Essential Guide for Improving your Health Naturally,,: Prima Publishing, Random House, Inc., New York. Pp. 194-198 (1996).

Examiner	Date Considered
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
*1 = Copy not submitted because it was submitted in prior application SN / _____, filed _____, 20____, relied on under 35 USC §120.	
*2 = Copy not submitted because it was submitted in prior application SN / _____, filed _____, 20____, relied on under 35 USC §120.	